secwatch.observer — SEC 8-K summary
======================================

Issuer:     AbbVie Inc. (ABBV)
CIK:        0001551152
Form:       8-K
Filed at:   2025-07-31T23:59:59+00:00
Accession:  0001551152-25-000036
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AbbVie Q2 adjusted EPS $2.97 (+12.1%); raises FY 2025 guidance to $11.88-$12.08
-------------------------------------------------------------------------------

- Q2 GAAP EPS $0.52 (down 32.5%); adjusted EPS $2.97 (+12.1%); revenue $15.423B (+6.6%).
- Immunology revenue $7.631B (+9.5%); Skyrizi $4.423B (+62.2%), Rinvoq $2.028B (+41.8%), Humira $1.180B (-58.1%).
- FY 2025 adjusted EPS guidance raised from $11.67-$11.87 to $11.88-$12.08; includes $0.55 IPR&D impact.
- Agreed to acquire Capstan Therapeutics (anti-CD19 CAR-T for autoimmune diseases); terms not disclosed.
- FDA approved Rinvoq for giant cell arteritis; Emrelis accelerated approval for c-Met high NSCLC.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/0001551152-25-000036-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1551152/000155115225000036/abbv-20250731.htm
  HTML page:      https://secwatch.observer/filing/0001551152-25-000036

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer